BriaCell Therapeutics: Jumps on expanding cancer drug pipeline
16/06/2021 13:56
** Shares of drug developer BriaCell Therapeutics Corp
BCTX.O jump ~19% to $7.18 premarket
** Co is expanding its breast cancer platform technology
into other indications including prostate, melanoma, and
non-small cell lung cancer (https://refini.tv/3gzGAzu)
** BCTX will pursue development of several novel
immunotherapy cell lines like Bria-Pros for prostate cancer,
Bria-Mel for melanoma, and Bria-Lung for lung cancer
** Expects commencing clinical trials for these therapies in
2022
** Co's lead candidate Bria-IMT has shown survival benefit
and disease control in patients with advanced breast cancer in
studies urn:newsml:reuters.com:*:nL3N2NK3I9
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study